Biotech Values

[dewophile]

I'm leery of the market moving forward, and bios in particular in advance of the Jan special election since a democratic controlled senate poses more risks wrt drug pricing. There are some bios like RVNC (aesthetic), ENTA (Hep C tx is cheap), FGEN (Roxa likely cheaper on healthcare system than epo - even biosimilar) that have lower risk when it comes to this, and in general I think Biden is less apt to be aggressive on the drug pricing front (war on cancer) esp on the heels of a pandemic.
On the more boring front GSK and GILD are quite cheap from a valuation standpoint and pay a nice dividend
But I am happy to be more in cash right now personally
I would be curious to hear other's takes and ideas too